Lurasidone
Small molecule
Also known as SM-13496
Evidence outlook
Approved: Schizophrenia, Bipolar Depression
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Treatment of schizophrenia and the improvement of depressive symptoms in patients with bipolar disorder
- Schizophrenia and bipolar depression
- Treatment of schizophrenia in adults aged 18 years and over.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00549718 NCT00549718 · Schizophrenia The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05). Registry: NCT00549718 | 3 | Change in Total PANSS Score From Baseline to the End of the Double Blind Phase (6 weeks) 2010-10 | Change in Total PANSS Score From Baseline to the End of the Double Blind Phase (6 weeks): Lurasidone 40mg -19.2 scores on a scale (95% CI -22.6 to -15.7) | Lurasidone 80mg -23.4 scores on a scale (95% CI -26.9 to -19.9) | Lurasidone 120mg -20.5 scores on a scale (95% CI -24 to -17.1) vs Placebo -17 scores on a scale (95% CI -20.5 to -13.6) | Reliable signal | link ↗ |
View 2 more trials
NCT00615433 NCT00615433 · Schizophrenia The study randomly assigned 478 participants to double-blind treatment with lurasidone, placebo, or olanzapine, with participants, care providers, and investigators masked. Its primary clinical endpoint, change in PANSS score at 6 weeks, showed a statistically significant favorable lurasidone-versus-placebo comparison (p<0.05), supporting strong evidence. Registry: NCT00615433 | 3 | Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period. (Baseline and 6 weeks) 2009-12 | Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period. (Baseline and 6 weeks): 40mg -25.7 Units on a scale (95% CI -29.6 to -21.8) | 120mg -23.6 Units on a scale (95% CI -27.8 to -19.4) vs 15mg Olz -28.7 Units on a scale (95% CI -32.4 to -24.9) | Placebo -16 Units on a scale (95% CI -20.1 to -12) | Reliable signal | link ↗ |
NCT03465787 NCT03465787 · Schizophrenia This was a randomized, double-blind, active-controlled non-inferiority trial in 210 patients that measured change in PANSS total score, a validated schizophrenia symptom scale, over 6 weeks. Lurasidone's effect was within the prespecified non-inferiority margin compared with quetiapine XR, confirming non-inferiority. Registry: NCT03465787 | 3 | Mean change in Total PANSS Score From Baseline at Week 6 2022-10-26 | Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (37)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (4)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Phase 4 (2)
What this study did
What this study did
Studied as part of a combination product (1)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 2 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other Dopamine D2/D3 receptor + 5-HT7 receptor drugs
LB-102 (methylated amisulpride). Compare all 2 Dopamine D2/D3 receptor + 5-HT7 receptor drugs
Other Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs
Asenapine, Clozapine, Iloperidone (Fanapt), Milsaperidone (VHX-896), Olanzapine (Zyprexa Relprevv) and 17 more. Compare all 23 Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs
This mechanism is crowded: 25 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Bipolar Depression: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lurasidone: this drug | Approved | Small molecule | Dopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| D-Cycloserine / Lurasidone (NRX-101) | Phase 3 | Small molecule | NMDA receptor (glycine site) + dopamine/5-HT receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-932 | Phase 1(overall) | Small molecule | Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
17 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Lurasidone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.